(Q37992679)

English

Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues

scientific article published on April 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

chronic obstructive pulmonary disease

1 reference

based on heuristic

inferred from title

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Maureen P M H Rutten-van Mölken

1

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Lucas M A Goossens

2

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

publication date

1 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

PharmacoEconomics

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

271-302

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

https://scigraph.springernature.com/pub.10.2165/11589270-000000000-00000

0 references

Chronic obstructive pulmonary disease. 5: systemic effects of COPD

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Health-related quality of life is related to COPD disease severity

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

The costs of exacerbations in chronic obstructive pulmonary disease (COPD).

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Toward a consensus definition for COPD exacerbations

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach.

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Impact of preventing exacerbations on deterioration of health status in COPD.

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Resource use and risk factors in high-cost exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Outcomes for COPD pharmacological trials: from lung function to biomarkers.

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

An economic overview of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD.

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Economic modeling in chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Health economics of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Optimizing economic outcomes in the management of COPD.

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD).

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD.

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

The cost effectiveness of early treatment with fluticasone propionate 250 microg twice a day in subjects with obstructive airway disease. Results of the DIMCA program.

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Cost effectiveness of budesonide/formoterol in a single inhaler for COPD compared with each monocomponent used alone

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study.

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Economic value of tiotropium in the treatment of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece.

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD.

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Cost-effectiveness of combination therapy for chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD.

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

The impact of combined inhaled bronchodilator therapy in the treatment of COPD.

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Assessing treatment effects of inhaled corticosteroids on medical expenses and exacerbations among COPD patients: longitudinal analysis of managed care claims.

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Using cost-effectiveness analysis to sharpen formulary decision-making: the example of tiotropium at the Veterans Affairs health care system

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Comparative cost-effectiveness analysis of theophylline and ipratropium bromide in chronic obstructive pulmonary disease. A three-center study

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Tiotropium's cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Tiotropium versus salmeterol for the prevention of exacerbations of COPD.

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

A New Method for Examining the Cost Savings of Reducing COPD Exacerbations

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Adequate Patient Characterization in COPD: Reasons to Go Beyond GOLD Classification

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Is the EQ-5D responsive to recovery from a moderate COPD exacerbation?

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Time course of recovery of health status following an infective exacerbation of chronic bronchitis

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

EuroQoL in assessment of the effect of pulmonary rehabilitation COPD patients.

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Utility estimation in chronic obstructive pulmonary disease: a preference for change?

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Do estimates of cost-utility based on the EQ-5D differ from those based on the mapping of utility scores?

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Assessing patient outcomes in acute exacerbations of chronic bronchitis: the measure your medical outcome profile (MYMOP), medical outcomes study 6-item general health survey (MOS-6A) and EuroQol (EQ-5D)

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease

1 reference

https://api.crossref.org/works/10.2165%2F11589270-000000000-00000

21 January 2018

COPD exacerbations: definitions and classifications.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22409290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Quality of life, stage severity and COPD

1 reference

https://pubmed.ncbi.nlm.nih.gov/22409290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Health status impairment and costs associated with COPD exacerbation managed in hospital

1 reference

https://pubmed.ncbi.nlm.nih.gov/22409290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhaled corticosteroids in COPD: a case in favour

1 reference

https://pubmed.ncbi.nlm.nih.gov/22409290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic assessment of initial maintenance therapy for chronic obstructive pulmonary disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22409290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacoeconomics in COPD: lessons for the future

1 reference

https://pubmed.ncbi.nlm.nih.gov/22409290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness and healthcare budget impact in Italy of inhaled corticosteroids and bronchodilators for severe and very severe COPD patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22409290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/22409290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22409290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization

1 reference

https://pubmed.ncbi.nlm.nih.gov/22409290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22409290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22409290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22409290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity

1 reference

https://pubmed.ncbi.nlm.nih.gov/22409290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhaled corticosteroids in COPD: the case against

1 reference

https://pubmed.ncbi.nlm.nih.gov/22409290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cost-effectiveness of combination fluticasone propionate-salmeterol 250/50 microg versus salmeterol in severe COPD patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22409290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic impact of using an immunostimulating agent to prevent severe acute exacerbations in patients with chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/22409290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reliability, validity and responsiveness of two multiattribute utility measures in patients with chronic obstructive pulmonary disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/22409290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD

1 reference

https://pubmed.ncbi.nlm.nih.gov/22409290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Worldwide burden of COPD in high- and low-income countries. Part I. The burden of obstructive lung disease (BOLD) initiative.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22409290

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2165/11589270-000000000-00000

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37992679&oldid=2150831623"